Daiichi Sankyo
Japanese global pharmaceutical company applying AI digital pathology and biomarker-discovery platforms across its oncology and ADC clinical programs.
- Company type
- Global pharmaceutical company
- Headquarters
- Tokyo, Japan
- Website
- https://www.daiichisankyo.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2026-03-25 — AI biomarker-discovery collaboration with Tempus AI (Tempus AI). Strategic collaboration using Tempus's AI-driven capabilities for biomarker discovery to support clinical differentiation across an antibody-drug conjugate (ADC) clinical program. Financial terms were not disclosed. Source: BioSpace (Tempus release) (accessed 2026-07-29)
- 2025-12-15 — AI digital-pathology collaboration with Lunit (Lunit). Collaboration applying Lunit's SCOPE IO and SCOPE universal IHC (uIHC) AI digital-pathology products across two Daiichi Sankyo oncology R&D programs to accelerate biomarker discovery and translational oncology research. Financial terms were not disclosed. Source: PR Newswire (Lunit release) (accessed 2026-07-29)